Stockreport

Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806
PDF VANCOUVER, British Columbia and WARMINSTER, Pa., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus ( [Read more]